Early Data For Bicycle’s Nectin-4 Asset Shows Promising Duration In Urothelial Cancer
Analysts Cautiously Optimistic
Executive Summary
The UK-headquartered biotech’s peptide-toxin conjugate showed a prolonged duration of response in advanced urothelial cancer patients in an early-stage trial compared with current standard of care, raising hopes for a differentiated profile.
You may also be interested in...
Bayer Saddles Up For Bicycle Radioconjugate Pact
The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
ESMO: Padcev/Keytruda Combo Edges Closer To First-Line Bladder Cancer Filing
Full data presented at ESMO from a closely watched trial of Seagen/Astellas’s Padcev and Merck & Co’s Keytruda should support regulatory approval of the combination in cisplatin-ineligible first-line metastatic urothelial cancer patients but concerns over duration of treatment remain.